PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
7032967-0	1981	Affinity labelling of yeast hexokinase with benzylamide derivatives of adenosine mono- and triphosphates bearing an alkylating group.	beclamide	44-55	hexokinase	Saccharomyces cerevisiae S288C	28-38
34726394-5	2021	In general, the diversification of the benzylamide moiety led to an enhanced selectivity over the most homologous isoform, Dyrk1B, which was a meaningful indicator, as the high selectivity could be confirmed in an extended selectivity profiling of 3b and 16b.	beclamide	39-50	dual specificity tyrosine phosphorylation regulated kinase 1B	Homo sapiens	123-129
25666822-1	2015	Replacement of the benzylamide motif of synthetic capsaicin (nonivamide, 1c) with a tetrazole moiety was detrimental for TRPV1 binding, but unexpectedly generated a potent and non-electrophilic TRPA1 agonist (4a).	beclamide	19-30	transient receptor potential cation channel subfamily A member 1	Homo sapiens	194-199
26725028-0	2016	Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity.	beclamide	0-11	F2R like trypsin receptor 1	Homo sapiens	27-56
26725028-4	2016	These findings show that new benzylamide antagonists of PAR2 have anti-inflammatory activity.	beclamide	29-40	F2R like trypsin receptor 1	Homo sapiens	56-60
32673902-0	2020	Novel anilide and benzylamide derivatives of arylpiperazinylalkanoic acids as 5-HT1A/5-HT7 receptor antagonists and phosphodiesterase 4/7 inhibitors with procognitive and antidepressant activity.	beclamide	18-29	5-hydroxytryptamine receptor 1A	Rattus norvegicus	78-84
32673902-1	2020	A library of novel anilide and benzylamide derivatives of omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkanoic acids as combined 5-HT1A/5-HT7 receptor ligands and phosphodiesterase PDE4B/PDE7A inhibitors was designed using a structure-based drug design approach.	beclamide	31-42	5-hydroxytryptamine receptor 1A	Rattus norvegicus	126-132
32673902-1	2020	A library of novel anilide and benzylamide derivatives of omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkanoic acids as combined 5-HT1A/5-HT7 receptor ligands and phosphodiesterase PDE4B/PDE7A inhibitors was designed using a structure-based drug design approach.	beclamide	31-42	phosphodiesterase 4B	Rattus norvegicus	178-183
32673902-1	2020	A library of novel anilide and benzylamide derivatives of omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkanoic acids as combined 5-HT1A/5-HT7 receptor ligands and phosphodiesterase PDE4B/PDE7A inhibitors was designed using a structure-based drug design approach.	beclamide	31-42	phosphodiesterase 7A	Rattus norvegicus	184-189
30688118-5	2019	The obtained benzylamides and piperazinoarylamides showed FAAH inhibition ranging from the low to high micromolar potency.	beclamide	13-25	fatty acid amide hydrolase	Homo sapiens	58-62
26922525-6	2016	CONCLUSION: The studied benzylamide derivatives can be arranged with respect to their anticonvulsant potency in the MEST test as follows: Nic-BZA>2F-Pic-BZA>Pic-BZA>Me-Ala-BZA>Iso-Nic-BZA>Me-Pro-BZA.	beclamide	24-35	mesoderm specific transcript	Mus musculus	116-120
19395260-1	2009	Benzylamides of pentanedioic acid were identified as inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) by high-throughput screening.	beclamide	0-12	RNA, U1 small nuclear 1	Homo sapiens	67-122
21853967-0	2011	Palladium-catalyzed alkylation of ortho-C(sp2)-H bonds of benzylamide substrates with alkyl halides.	beclamide	58-69	Sp2 transcription factor	Homo sapiens	40-45
18286621-2	2009	Affinity electrophoresis analysis provided evidence that carboxymethylated dextran polymers grafted with high amounts of benzylamide groups (named DMCB) interact with BMP-2.	beclamide	121-132	bone morphogenetic protein 2	Homo sapiens	167-172
18286621-5	2009	A screening study provided evidence that the potentiating effects of the dextran derivatives on the BMP-2-induced alkaline phosphatase activity improved with their benzylamide groups content and, therefore, with their affinity for the growth factor.	beclamide	164-175	bone morphogenetic protein 2	Homo sapiens	100-105
18065096-6	2007	In the benzylamide analogue of MPCB (compound 9) the presence of a third aromatic nucleus, at an appropriate distance and conformation with respect to aromatic pharmacophoric residues, increased KOP receptor affinity by about 6-fold compared to MPCB (Ki = 35 nM and Ki = 240 nM, respectively).	beclamide	7-18	serine peptidase inhibitor, Kunitz type 2	Homo sapiens	195-198
18215519-2	2008	Evaluation of CCR2 binding affinities for these analogs gave insight into the optimal relative positions of the piperidine and benzylamide moieties while simultaneously leading to the discovery of a new, potent lead type based upon a spirocyclic acetal scaffold.	beclamide	127-138	C-C motif chemokine receptor 2	Homo sapiens	14-18
15576151-1	2005	Functionalized dextrans (FD) are anionic water-soluble polymers bearing carboxylate, benzylamide and sulfate groups, which exhibit binding capacity to transforming growth factor-beta1 (TGF-beta1).	beclamide	85-96	transforming growth factor beta 1	Homo sapiens	151-183
17107799-2	2007	Extensive SAR around the benzylamide moiety led to the identification of the p-fluorobenzylamide as optimal in the enzymatic assay.	beclamide	25-36	sarcosine dehydrogenase	Homo sapiens	10-13
15576151-1	2005	Functionalized dextrans (FD) are anionic water-soluble polymers bearing carboxylate, benzylamide and sulfate groups, which exhibit binding capacity to transforming growth factor-beta1 (TGF-beta1).	beclamide	85-96	transforming growth factor beta 1	Homo sapiens	185-194
10889187-5	2000	We show that dextran containing carboxymethyl, sulfate as well as benzylamide groups (RG1192 compound), was the most efficient inhibitor of plasmin amidolytic activity.	beclamide	66-77	plasminogen	Homo sapiens	140-147
14609277-0	2003	Synthesis of benzylamides of dipeptides as potential inhibitors of plasmin.	beclamide	13-25	plasminogen	Homo sapiens	67-74
14609277-1	2003	Four benzylamides of dipeptides with the general formula: X-L-Lys-NH-CH2-C6H5, where X = L-or D-Leu and L-or D-Phe were prepared as potential inhibitors of plasmin.	beclamide	5-17	plasminogen	Homo sapiens	156-163
12606025-3	2003	Dextran containing carboxymethyl and benzylamide groups (RG1150) as well as those containing carboxymethyl, sulfate and benzylamide groups (RG1192), were the most efficient inhibitors of CatG activity.	beclamide	120-131	cathepsin G	Homo sapiens	187-191
10353261-13	1999	The carboxymethyl and benzylamide groups of these molecules likely interact directly with a heparin-binding region of FGF-2.	beclamide	22-33	fibroblast growth factor 2	Homo sapiens	118-123
9641623-7	1998	A kinetic study showed that all the CMDBS exhibited higher affinity for thrombin than heparin did but lower affinity than DXSu did, suggesting that the benzylamide and sulfate groups potentiate the interaction between the dextran derivatives and thrombin.	beclamide	152-163	coagulation factor II, thrombin	Homo sapiens	72-80
9641623-7	1998	A kinetic study showed that all the CMDBS exhibited higher affinity for thrombin than heparin did but lower affinity than DXSu did, suggesting that the benzylamide and sulfate groups potentiate the interaction between the dextran derivatives and thrombin.	beclamide	152-163	coagulation factor II, thrombin	Homo sapiens	246-254